Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Murphy

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 20, 2004
The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery diseaseJoseph Murphy, R Scott Wright, Ihor Gussak, et al.
JAMA Surgery|July 7, 2021
Development and Validation of Image-Based Deep Learning Models to Predict Surgical Complexity and Complications in Abdominal Wall ReconstructionSharbel Adib Elhage, Eva Barbara Deerenberg, Sullivan Armando Ayuso, et al.
Circulation. Heart Failure|January 19, 2021
Defining Shock and Preshock for Mortality Risk Stratification in Cardiac Intensive Care Unit PatientsJacob C Jentzer, Barry Burstein, Sean Van Diepen, et al.
The American Journal of Cardiology|October 7, 2021
Relation of Left Ventricular Assist Device Infections With Cardiac Transplant OutcomesAditya Parikh, Michael Halista, Samantha Raymond, et al.
Research Square|April 24, 2023
New insights into the responder/nonresponder divide in rectal cancer: Damage-induced Type I IFNs dictate treatment efficacy and can be targeted to enhance radiotherapyScott Gerber, Taylor Uccello, Maggie Lesch, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2019
Loss of MPC1 reprograms retinal metabolism to impair visual functionAllison Grenell, Yekai Wang, Michelle Yam, et al.
Clinical and Translational Science|March 18, 2024
First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromeRupa Narayan, Ana Alfonso Piérola, William B Donnellan, et al.
British Journal of Haematology|July 2, 2025
A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDSEmma Searle, Thomas Cluzeau, Jenny O'Nions, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 20, 2004
The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery diseaseJoseph Murphy, R Scott Wright, Ihor Gussak, et al.
JAMA Surgery|July 7, 2021
Development and Validation of Image-Based Deep Learning Models to Predict Surgical Complexity and Complications in Abdominal Wall ReconstructionSharbel Adib Elhage, Eva Barbara Deerenberg, Sullivan Armando Ayuso, et al.
Circulation. Heart Failure|January 19, 2021
Defining Shock and Preshock for Mortality Risk Stratification in Cardiac Intensive Care Unit PatientsJacob C Jentzer, Barry Burstein, Sean Van Diepen, et al.
The American Journal of Cardiology|October 7, 2021
Relation of Left Ventricular Assist Device Infections With Cardiac Transplant OutcomesAditya Parikh, Michael Halista, Samantha Raymond, et al.
Research Square|April 24, 2023
New insights into the responder/nonresponder divide in rectal cancer: Damage-induced Type I IFNs dictate treatment efficacy and can be targeted to enhance radiotherapyScott Gerber, Taylor Uccello, Maggie Lesch, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 28, 2019
Loss of MPC1 reprograms retinal metabolism to impair visual functionAllison Grenell, Yekai Wang, Michelle Yam, et al.
Clinical and Translational Science|March 18, 2024
First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromeRupa Narayan, Ana Alfonso Piérola, William B Donnellan, et al.
British Journal of Haematology|July 2, 2025
A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDSEmma Searle, Thomas Cluzeau, Jenny O'Nions, et al.
Pageof 8